Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (June 2026)
24 slides from Nyrada's investor presentation, Jun 4, 2026
Slide 1: Investor Presentation June 2026
For personal use only Investor Presentation June 2026 ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase a
Slide 3: Investment Highlights
Investment Highlights Advancing first-in-class TRPC inhibitor with multiple near-term value catalysts For personal use only Platform asset with Positive Phase I Near term Phase IIa High unmet need Strong IP & Uniquely Multiple near-term data supporting safety and kinetic safety and efficacy opportun
Slide 4: About Nyrada
About Nyrada Nyrada is pioneering TRPC-targeted therapies, providing exposure to an emerging and increasingly recognised therapeutic area For personal use only › Nyrada Inc (ASX:NYR) is a clinical-stage biotechnology company developing a first-in-class small molecule Transient Receptor Potential Can
Slide 5: Management
Management Highly experienced and a proven track record of delivering shareholder value For personal use only Leadership Team Jasneet James Bonnar Benny Evison Alex Parmar Dimitri Burshtein Managing Ph.D Suchowerska Ph.D Director of Investor Director & CEO Chief Scientific Ph.D Relations and Directo
Slide 6: Board of Directors
Board of Directors Highly experienced and a proven track record of delivering shareholder value For personal use only Board Members John Moore Christopher Marcus Dr Rüdiger Dr Ian Dixon James Bonnar Non-Executive Cox Frampton Weseloh Non-Executive Managing Director Chairman Non-Executive Non-Executi
Slide 7: Xolatryp®
Xolatryp® Nyrada’s lead candidate Xolatryp® is a novel gatekeeper of calcium influx with wide applicability For personal use only Overview Cardioprotection • Xolatryp® is a third generation TRPC3/6/7 channel inhibitor TRPC3 TRPC6 TRPC7 • Highly differentiated, proven target with well understood mech
Slide 8: Xolatryp® multi-indication platform
Xolatryp® Highly focused multi-indication platform addressing high unmet need in well-defined markets For personal use only 1 Candidate Xolatryp® 3 Current Cardioprotection Oncology Neuroprotection Applications (secondary brain injury) Cardiac Reperfusion Injury Adjunct in Anthracycline-treated Trau
Slide 9: Xolatryp® Phase I Clinical Trial
Xolatryp® Phase I Clinical Trial Primary endpoint met with all doses safe and well-tolerated, with no dose-limiting, or dose-related safety issues For personal use only Trial Overview • Phase I, randomised, double-blind, placebo-controlled study in 48 healthy volunteers • 36 received Xolatryp®, 12 r
Slide 10: Diversified Pipeline
Diversified Pipeline Multiple compelling TRPC opportunities in indications of high unmet need For personal use only Target Applications Pre-clinical Phase I Phase II Phase III Indication Cardiac Phase IIa Cardioprotection Reperfusion Injury Recruiting Post STEMI Chemotherapy Proof of concept Induced
Slide 11: TRPC Channels: Clinical Landscape & Validation
TRPC Channels: Clinical Landscape & Validation Growing Clinical Interest in TRPC modulation across major disease areas For personal use only • Genetic validation and strong preclinical data have led to advancing clinical programs First TRPC Program to Reach Phase III across cardiovascular, kidney, n
Slide 12: Xolatryp® in Cardiac Reperfusion Injury
For personal use only Xolatryp® in Cardiac Reperfusion Injury Well defined & uncontested $US3bn market opportunity
Slide 13: Heart Attack (STEMI)
Heart Attack (STEMI) STEMI results in a hyper-activation of TRPC channels For personal use only Overview STEMI • Atherosclerotic plaque restricts blood flow to a region of the heart muscle resulting in Myocardial Infarction (MI) “Heart attack” • STEMI (ST-elevation myocardial infarction) is a blocka
Slide 14: Current Standard Treatment for STEMI Heart Attack
Current Standard Treatment for STEMI Heart Attack Up to ~50% of heart injury may be caused by reperfusion For personal use only Infarct size as a driver of heart failure Current Standard of Care for The Clinical Paradox from PCI risk and mortality STEMI patients Review of multiple clinical studies s
Slide 15: Large, Uncontested Market Opportunity
Large, Uncontested Market Opportunity A large, uncontested US$3bn US opportunity For personal use only US Market Opportunity ~750K >80% ~600K US$5,000 US$3bn = STEMI¹ STEMI related PCI¹ Illustrative price² ✕ ✕ Total addressable Estimated PCI market in the US Annual STEMI Illustrative price procedure
Slide 16: Xolatryp® Cardioprotective Function
Xolatryp® Cardioprotective Function Strong, consistent cardioprotection across models of myocardial infarction For personal use only Two preclinical studies evaluated Xolatryp® in myocardial ischemia-reperfusion (I/R) injury models. One assessed early arrhythmia events and biomarkers over 3 hours, t
Slide 17: PROTECT-MI: Phase IIa Trial Design
PROTECT-MI: Phase IIa Trial Design Phase IIa cardiac reperfusion Injury clinical trial currently recruiting For personal use only PROTECT-MI is a Phase IIa randomised, double-blind, placebo-controlled study 100 evaluable patients (placebo and drug evaluating Xolatryp® in STEMI patients undergoing PC
Slide 18: Other Indications across Oncology & Neuroprotection
For personal use only Other Indications across Oncology & Neuroprotection
Slide 19: Oncology
Oncology Xolatryp® enhances anthracycline anti-tumour efficacy For personal use only Xolatryp® Enhances Standard Chemotherapy Efficacy ANTI-PROLIFERATIVE • Novel TRPC3/6/7 inhibitor targeting calcium-dependent tumour growth pathways Cancer Treatment • Anthracyclines remain a cornerstone of cancer tr
Slide 20: Neuroprotection
Neuroprotection Xolatryp® targets secondary injury following ischemic stroke and traumatic brain injury For personal use only Overview • Ischemic stroke and traumatic brain injury (TBI) trigger secondary injury pathways that drive ongoing neuronal damage • Excess intracellular Ca²⁺ is a key mediator
Slide 21: Catalysts
Catalysts Upcoming milestones over the next 18 months For personal use only 2H CY26 1H CY27 2H CY27 • PROTECT-MI Phase IIa execution: ongoing patient • PROTECT-MI Phase IIa execution: ongoing • Phase IIa PROTECT-MI completion and topline recruitment and site activations across Australian patient rec
Slide 22: Appendix
For personal use only Appendix
Slide 23: Corporate Overview & Financial Snapshot
Corporate Overview & Financial Snapshot Key Details Share Price Chart – Last 24 months For personal use only Stock Code ASX:NYR Share Price (1 June 2026) A$0.48 $1.40 Number of CDIs on Issue 245m Market Capitalisation (1 June 2026) A$119.0m $1.20 Pro forma Cash Balance (31 March 2026)1 A$9.19m $1.00
Slide 24: Program Links
Program Links For personal use only • PROTECT-MI website - https://www.protect-mi.com • Corporate presentation/about MI - https://bit.ly/4dDWNCz • Phase IIa factsheet - https://bit.ly/4bcDlKj • Phase I results - https://bit.ly/3Nt0GzH • GLP study results - https://bit.ly/4d8VYkX • Preclinical anti-t